According to GlobalData’s medical device pipeline database, 14 KRAS Tests devices are in various stages of development globally. GlobalData’s report KRAS Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, nine are in active development, while the remaining five are in an inactive stage of development. There are two products in the early stages of development, and the remaining seven are in the late stages of development.

In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The KRAS test is a genetic test that looks for mutations in the KRAS gene. Kirsten rat sarcoma virus (KRAS) gene tests are carried out to detect gene mutations in patient tissue samples; the outcome of which may guide therapies to treat various cancers including colorectal cancer, certain lung cancers and some leukemias. The KRAS gene is a proto-oncogene, which means that it can become an oncogene (a cancer-causing gene) if it mutates. Mutations in the KRAS gene are found in about 35% of colorectal cancers and about 15% of non-small cell lung cancers. Colorectal cancer (CRC) is classified based on the stage of the disease at diagnosis. CRC has been divided into localized, regional metastasis, and distant metastasis. Localized CRC is defined as cancer that has not yet metastasized. Regional metastasis refers to cancer that has spread to the lymph nodes near the colon or rectum. Distant metastasis refers to cancer that has spread to other organs of the body such as the lungs. There are two other widely used systems to classify CRC. The first groups CRC into stages -IV and the second use a lettering system (A-D). GlobalData considers stage -II & A-B as localized, stage III & stage C as regional metastasis, and stage IV & stage D as distant metastasis. The KRAS Tests market includes Colorectal Cancer Stages of Diagnosis, Sanger Sequencing Tests; Nucleic Acid Amplification Tests (NAATs), and Other KRAS Tests.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed KRAS Tests pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of KRAS Tests devices. Overall, most of these KRAS Tests pipeline devices are being developed by private entities.

Key players involved in the active development of KRAS Tests include Abbott Diagnostics, Biocartis Group, Exosomics Siena, GeneCast Biotechnology, GeneCentric Therapeutics, GenMark Diagnostics, Guardant Health, MiraDx, Resolution Bioscience and Rheonix.

For a complete picture of the developmental pipeline for KRAS Tests devices, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.